Sagimet Biosciences (SGMT) Cash from Investing Activities (2022 - 2026)

Sagimet Biosciences' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at $10.2 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 199.33% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $11.4 million (up 118.54% YoY), while the FY2025 annual figure was $4.6 million, up 107.39% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $10.2 million, down from $14.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $19.4 million in Q1 2023, with the low at -$75.2 million in Q2 2024.
• The 5-year median for Cash from Investing Activities is $3.7 million (2022), against an average of -$1.8 million.
• The sharpest annual moves came in 2024 and 2026: Cash from Investing Activities tumbled 687.16% in 2024, then jumped 199.33% in 2026.
• Sagimet Biosciences' Cash from Investing Activities stood at $5.4 million in 2022, then plunged by 460.93% to -$19.6 million in 2023, then surged by 150.2% to $9.8 million in 2024, then jumped by 45.77% to $14.4 million in 2025, then declined by 28.85% to $10.2 million in 2026.
• Business Quant data shows SGMT's Cash from Investing Activities at $10.2 million in Q1 2026, $14.4 million in Q4 2025, and $75000.0 in Q3 2025.